Publications by authors named "Narina Sargsyants"
Article Synopsis
- A study on Hepatitis C virus (HCV) in Armenia found a 2% prevalence of anti-HCV antibodies and 0.7% prevalence of chronic HCV infection among 3,831 adults sampled across the country.
- Common HCV genotypes identified were types 3 and 2, highlighting the need for targeted treatment strategies.
- Key risk factors associated with chronic HCV infection included having chronic liver disease, tattoos, smoking, and past hepatitis B infection, suggesting areas for improved infection control measures in the region.
Objectives: This study sought to determine the prevalence and associated factors of hepatitis B virus (HBV) infection ever in life and chronic HBV infection in Armenia.
Design: A population-based cross-sectional seroprevalence study combined with a phone survey of tested individuals.
Setting: All administrative units of Armenia including 10 provinces and capital city Yerevan.
During the first half of 2022, the World Health Organization reported an outbreak of acute severe hepatitis of unknown aetiology (AS-Hep-UA) in children, following initial alerts from the United Kingdom (UK) where a cluster of cases was first observed in previously well children aged <6 years. Sporadic cases were then reported across Europe and worldwide, although in most countries incidence did not increase above the expected baseline. There were no consistent epidemiological links between cases, and microbiological investigations ruled out known infectious causes of hepatitis.
View Article and Find Full Text PDFThe increased antiretroviral therapy (ART) coverage of patients in the absence of routine genotyping tests and in the context of active labor migration highlight the importance of HIV-1 drug resistance (DR) surveillance in Armenia. We conducted a two-phase pretreatment DR (PDR) study in 2017-2018 (phase I; 120 patients) and 2020-2021 (phase II; 133 patients) according to the WHO-approved protocol. The analysis of HIV-1 genetic variants showed high degrees of viral diversity, with the predominance of A6.
View Article and Find Full Text PDFWe assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.
View Article and Find Full Text PDF